$130 Million is the total value of Abingworth LLP's 11 reported holdings in Q2 2013. The portfolio turnover from Q1 2013 to Q2 2013 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMRN | New | Amarinspons adr | $46,827,000 | – | 8,087,486 | +100.0% | 36.03% | – |
| PTLA | New | Portola | $30,502,000 | – | 1,240,917 | +100.0% | 23.47% | – |
| SUPN | New | Supernus | $23,184,000 | – | 3,600,000 | +100.0% | 17.84% | – |
| ALNY | New | Alnylam | $9,689,000 | – | 313,053 | +100.0% | 7.45% | – |
| OGXI | New | Oncogenex Pharma | $5,917,000 | – | 603,740 | +100.0% | 4.55% | – |
| CEMP | New | Cempra | $5,593,000 | – | 714,285 | +100.0% | 4.30% | – |
| ZGNX | New | Zogenix | $4,017,000 | – | 2,335,218 | +100.0% | 3.09% | – |
| ANTH | New | Anthera | $1,727,000 | – | 3,503,956 | +100.0% | 1.33% | – |
| HPTX | New | Hyperion | $1,376,000 | – | 62,500 | +100.0% | 1.06% | – |
| GWPH | New | GW Pharma (US)ads | $879,000 | – | 102,200 | +100.0% | 0.68% | – |
| ZLCS | New | Zalicus | $268,000 | – | 473,800 | +100.0% | 0.21% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Abingworth Management LTD #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-NT | 2024-08-09 |
| 13F-NT | 2024-05-03 |
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.